Leveraging Emerging Markets and Technologies in Life Sciences
Date: January 8, 2012, Sunday, 8.00 am - 7.00 pm
Venue: Westin San Francisco Airport, 1 Old Bayshore Hwy, Millbrae, CA 94030.
The EPPIC annual life science conference combines networking, mentoring, keynote lectures and panel discussions on current topics. The annual conference also focuses on promoting cross border (US-India) collaborations and attracts multiple individuals and organizations interested in leveraging potential synergies. This year's panels should give attendees a good grasp of the latest trends in industry: Personalized Medicine, Pre-clinical CROs, “Speed Pitch” presentations by Life Sciences start-ups, and Biologics/Biosimilars will. The annual conference will also feature a speed networking session to promote interaction among attendees. The conference brings budding and seasoned entrepreneurs, senior executives, scientists, venture capitalists and legal experts, together to tell their stories and will attract potential partners, employees and investors.
Registration: Early Bird Registration: $100 (ends on Dec 26th, 11.55 pm)
Advance Registration: $125 (Dec 27 - Jan 7th, 11.55 am)
On site Registration: $150 (Jan 8th 7.30 am - 1 pm)
Student/Postdoc registration: $50 (ends by Dec 26th, only first 25 will be allowed). A valid ID must be shown. Otherwise, they will be considered as a regular attendee.
Registration fee is waived for Charter Members (please write to "eppicglobal@gmail.com" for charter membership benefits), if you are interested in becoming a Charter Member for the 2012 calendar year.
Attendees who plan to register through check option must send the check payable to "EPPIC GLOBAL" and mail the check to EPPIC mailing address (EPPIC GLOBAL NETWORK, PMB# 402, 4546 El Camino Real, Suite B-10, Los Altos, CA 94022-1069) no later than Dec 31st, 2011.
Checks received after Dec 31st considered as on-site registration and you will have to pay additional $50 ($150 instead of $100).
No refunds on registration fee. But transferring the registration fee to another attendee can be considered by only prior written request to "eppicglobal@gmail.com".
Registration fee to EPPIC 2012 Annual Conference includes EPPIC Annual Membership ($50), breakfast, coffee, reception (hors'd'oeuvres, light refreshments) and access to sponsor information booths, etc. Student registration fee does not include Annual membership fee. Please note that registration fee is at substantially discounted price to all attendees due to generous sponsorship from Life Science corporations and 100% volunteer work by organizing committee to reduce overhead costs. Please help us spreading the word on EPPIC 2012 Annual Conference to all Life Science professionals.
This panel will evaluate personalized medicine within the context of patients being treated with specific therapies based on their genetic makeup such as mutations, genotype, and specific biomarkers. Herceptin was one of the first drugs to be approved by the FDA with a companion diagnostic on its label. After a gap of nearly thirteen years, recently new drugs such as Zelboraf and Xalkori have been approved with a well-defined target patient population. Our panelists will discuss how basic science discoveries are shaping drug development plans, and how this all fits into the new paradigm of medicine where pricing and reimbursement issues are as important as science for the competitive positioning of products.
11.45 am - 12.30 pm
Speed Networking: An opportunity to meet over 100 attendees by three minute quick introductions with a group of three attendees and also in a group setting. Please bring ~150 business cards.
12.30 - 1.30 pm
Lunch Break
1.30 - 2.00 pm
Keynote Address 2: A DECADE OF THE DRAGON AND THE TIGER DEALING WITH THE EAGLE
Jon Northrup, CEO, Beta Cat PHARMACEUTICALS
Collaborative drug development across China and India, supporting US and European Pharmas, has been evolving for some time. No major pharma executive can afford to not have global experience on their resume today. What has been learned, and how are Asian companies creating the next big pharmaceutical and biotech companies. What are the differences in working on either side of the world?
2.00 - 2.45 pm
Panel 2: IDEAS TO IND: GET GLOBAL
Moderator:Chitra Sharma, President, gCompliance Panelists: Jay De La Cruz, President and Founder, InTouch BioSolutions Tony Zhang, CEO, Formurex Philip Teitelbaum, Executive Director, Molecule Development Group, Covance
Dramatic improvements in capabilities and talent across the globe have enabled opportunities for companies offering high quality pre-clinical contract research services. This panel will provide a perspective from geographies such as China, India and Eastern Europe, and highlight do's, don'ts and best practices for successful engagements.
2.45 - 3.15 pm
Keynote Address 3: WHY EMERGING MARKETS ARE CRITICAL TO MEDICAL TECHNOLOGY INNOVATION
Geetha Rao, CEO, Springborne Life Sciences & Vice President, Corporate Development, Triple Ring Technologies
With continued economic growth in emerging market countries, expectations for healthcare are rising to levels comparable to those of developed countries. This requires large-scale, relatively low-cost, and rapid deployment of healthcare delivery capabilities. At the same time, skyrocketing healthcare costs in the US have accelerated the need for more effective and cost-effective methods for delivering care. The most promising innovations are targeting early and less expensive interventions through consumer electronics coupled with mobile technologies. In the US, devices already on the market include fitness and health maintenance devices, and home monitoring devices for cardiac rhythms, blood pressure, blood glucose, sleep quality, and a variety of other biometrics. However, as these technologies attempt to become more formally “medicalized,” they face daunting regulatory hurdles and the challenges of an incumbent healthcare culture. This makes emerging markets much more attractive for initial product launches and for piloting care delivery innovations. This talk will explore the trends and opportunities in this area.
Entrepreneurs in early stage companies in the life sciences are invited to give a five-minute pitch about their idea, technology, and company. They will present to the entire audience, obtain quick feedback from a distinguished VC panel (Artiman, Soffinova, Lumira, SR1), and get exposure to various potential collaborators, partners.
4.30 - 5.00 pm
Keynote Address 4: BIOSIMILARS - AN OVERVIEW
Timothy L. Moore, Senior Vice President, Genentech & Global Head Pharmaceutical Technical Operations Biologics Unit, Roche
Biosimilars continue to be a highly debated and discussed topic in the Pharmaceutical industry. This keynote will provide a high level overview on biosimilars, specifically biosimilar antibodies and the challenges and paradigms that surround the production of biosimilars. A high level overview of the current regulatory landscape will be provided from a global perspective and briefly touch upon some of the prevailing market dynamics to provide the audience some considerations for biosimilar antibodies.
5.00 - 6.00 pm
Panel 4: THE BIOLOGICS(R) EVOLUTION: GENERICS, SIMILARS, BETTERS AND SUPERIORS
Moderator: Mohan Srinivasan, Director, Bristol-Myers Squibb/Medarex Panelists: Stephen Keane, President and CEO, Femta Biopharmaceuticals Trevor Hallam, CSO, Sutro Biopharma
Ramesh Bhatt, Vice President Research, Sea Lane Biotechnologies
Recombinant biological therapeutics or Biologics are difficult to manufacture with consistency due to their extreme complexity in composition and structure. Biosimilars or Follow-on-Biologics (FOB) are generic versions of the Biologics that are coming off patent protection, promising equivalent safety and efficacy, but costing several folds less than the original version. In the next 5 years, patent exclusivity expires on more than half-a-dozen Biologics, and the FOB market is expected to grow to $20 Billion by 2014, leading to a surge in efforts to capture these growing opportunities. Development of FOB in BRIC countries have expanded by leaps and bounds. Established players include Teva, Sandoz, Hexal, etc. Merck recently started a FOB division to capture this expanding market space. Still, many challenges lie ahead with the cost of developing one FOB pegged around $100M including continuing lack of a clear regulatory pathway in the US. This track will bring in leaders with manufacturing, marketing and regulatory experience in Biologics to discuss the opportunities and challenges."
6.00 - 6.15 pm
Closing remarks:Pradeep Fernandes, Conference Co-Chair, Founder & President, Cellworks Group
6.15 - 7.30 pm
Evening Reception: Cocktails and light refreshments
